ULGX Stock Overview

Develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. More details

ULGX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($2K)

Latest financial reports are more than a year old

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Urologix, Inc. Competitors

Lucira Health

OTCPK:LHDX.Q

US$4.2k

Motus GI Holdings

OTCPK:MOTS

US$1.4k

ThermoGenesis Holdings

OTCPK:THMO

US$11.1k

ViewRay

OTCPK:VRAY.Q

US$18.3k

Price History & Performance

Summary of share price highs, lows and changes for Urologix
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.04
52 Week Low	US$0.000001
Beta	0
1 Month Change	9,900.00%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	9,900.00%
5 Year Change	-97.22%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ULGX	US Medical Equipment	US Market
7D	0%	-2.1%	-2.6%
1Y	n/a	9.9%	24.5%

Return vs Industry: Insufficient data to determine how ULGX performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how ULGX performed against the US Market.

Price Volatility

Is ULGX's price volatile compared to industry and market?
ULGX volatility
ULGX Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ULGX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ULGX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1991	n/a	Bryon Merade	www.urologix.com

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms.

Urologix, Inc. Fundamentals Summary

How do Urologix's earnings and revenue compare to its market cap?
ULGX fundamental statistics
Market cap	US$2.13k
Earnings (TTM)	-US$4.67m
Revenue (TTM)	US$12.00m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ULGX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ULGX income statement (TTM)
Revenue	US$12.00m
Cost of Revenue	US$6.34m
Gross Profit	US$5.66m
Other Expenses	US$10.32m
Earnings	-US$4.67m

Last Reported Earnings

Mar 31, 2015

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ULGX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 04:23
End of Day Share Price	2024/12/20 00:00
Earnings	2015/03/31
Annual Earnings	2014/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Urologix, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ernest Andberg	Feltl and Company, Inc.